Ofatumumab OverviewOfatumumab, sold under the brand name Arzerra among others, is a fully human monoclonal antibody to CD20, which appears to inhibit early-stage B lymphocyte activation. It is FDA approved for treating chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab (Campath) and for the treatment of multiple sclerosis. It has also shown potential in treating follicular lymphoma, diffuse large B cell lymphoma, rheumatoid arthritis. Ofatumumab is the first market...
Read more Ofatumumab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ofatumumab
Recent Ofatumumab Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 100mg/5ml
- Solution: 20mg/0.4ml
NDC Database Records for Ofatumumab: (1 result)Sorted by National Drug Code
- 0078-1007 Kesimpta 20 mg/.4ml Subcutaneous Injection, Solution by Novartis Pharmaceuticals Corporation
Other drugs which contain Ofatumumab or a similar ingredient: (1 result)
- ARZERRA Ofatumumab